Literature DB >> 11349053

Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

R D Hardy1, H S Jafri, K Olsen, M Wordemann, J Hatfield, B B Rogers, P Patel, L Duffy, G Cassell, G H McCracken, O Ramilo.   

Abstract

Because Mycoplasma pneumoniae is hypothesized to play an important role in reactive airway disease/asthma, a comprehensive murine model of M. pneumoniae lower respiratory infection was established. BALB/c mice were intranasally inoculated once with M. pneumoniae and sacrificed at 0 to 42 days postinoculation. All mice became infected and developed histologic evidence of acute pulmonary inflammation, which cleared by 28 days postinoculation. By contrast, M. pneumoniae persisted in the respiratory tract for the entire 42 days studied. Tumor necrosis factor alpha, gamma interferon, interleukin-6 (IL-6), KC (functional IL-8), MIP-1alpha, and MCP-1/JE concentrations were significantly elevated in bronchoalveolar lavage samples, whereas IL-4 and IL-10 concentrations were not significantly elevated. Pulmonary airflow resistance, as measured by plethysmography, was detected 1 day postinoculation and persisted even after pulmonary inflammation had resolved at day 28. Serum anti-M. pneumoniae immunoglobulin G titers were positive in all mice by 35 days. This mouse model provides a means to investigate the immunopathogenesis of M. pneumoniae infection and its possible role in reactive airway disease/asthma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349053      PMCID: PMC98411          DOI: 10.1128/IAI.69.6.3869-3876.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia.

Authors:  C K Kim; C Y Chung; J S Kim; W S Kim; Y Park; Y Y Koh
Journal:  Pediatrics       Date:  2000-02       Impact factor: 7.124

2.  The results of pulmonary function tests in patients infected with Mycoplasma pneumoniae.

Authors:  J P Dierckx; C Gillard
Journal:  Infection       Date:  1976       Impact factor: 3.553

Review 3.  Mycoplasma pneumoniae disease: clinical spectrum, pathophysiology, epidemiology, and control.

Authors:  F W Denny; W A Clyde; W P Glezen
Journal:  J Infect Dis       Date:  1971-01       Impact factor: 5.226

4.  Shedding of Mycoplasma pneumoniae after tetracycline and erythromycin therapy.

Authors:  C B Smith; W T Friedewald; R M Chanock
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

5.  Epidemiology of Mycoplasma pneumoniae infection in families.

Authors:  H M Foy; J T Grayston; G E Kenny; E R Alexander; R McMahan
Journal:  JAMA       Date:  1966-09-12       Impact factor: 56.272

6.  Effect of MALP-2, a lipopeptide from Mycoplasma fermentans, on bone resorption in vitro.

Authors:  G Piec; J Mirkovitch; S Palacio; P F Mühlradt; R Felix
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

7.  Modulation of cytokine profiles by the Mycoplasma superantigen Mycoplasma arthritidis mitogen parallels susceptibility to arthritis induced by M. arthritidis.

Authors:  H H Mu; A D Sawitzke; B C Cole
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Pulmonary function in children with Mycoplasma pneumoniae pneumonia.

Authors:  B Kjellman
Journal:  Infection       Date:  1976       Impact factor: 3.553

Review 9.  Role of cytokines in pulmonary antimicrobial host defense.

Authors:  B Mehrad; T J Standiford
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

10.  Mycoplasma pneuminia infection. A follow-up study of 50 children with respiratory illness.

Authors:  J Y Mok; P R Waugh; H Simpson
Journal:  Arch Dis Child       Date:  1979-07       Impact factor: 3.791

View more
  41 in total

1.  Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

Authors:  T R Kannan; Jacqueline J Coalson; Marianna Cagle; Oxana Musatovova; R Doug Hardy; Joel B Baseman
Journal:  J Infect Dis       Date:  2011-09-28       Impact factor: 5.226

2.  Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Authors:  Chonnamet Techasaensiri; Claudia Tagliabue; Marianna Cagle; Pooya Iranpour; Kathy Katz; Thirumalai R Kannan; Jacqueline J Coalson; Joel B Baseman; R Doug Hardy
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

3.  Antibodies to Protein but Not Glycolipid Structures Are Important for Host Defense against Mycoplasma pneumoniae.

Authors:  Patrick M Meyer Sauteur; Adrianus C J M de Bruijn; Catarina Graça; Anne P Tio-Gillen; Silvia C Estevão; Theo Hoogenboezem; Rudi W Hendriks; Christoph Berger; Bart C Jacobs; Annemarie M C van Rossum; Ruth Huizinga; Wendy W J Unger
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

4.  Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation.

Authors:  Jorge L Medina; Jacqueline J Coalson; Edward G Brooks; Vicki T Winter; Adriana Chaparro; Molly F R Principe; Thirumalai R Kannan; Joel B Baseman; Peter H Dube
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

5.  Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Ana María Ríos; Mónica Fonseca-Aten; Asunción Mejías; Susana Chávez-Bueno; Kathy Katz; Ana María Gómez; George H McCracken; Octavio Ramilo; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 6.  Asthma exacerbations. 2: aetiology.

Authors:  A M Singh; W W Busse
Journal:  Thorax       Date:  2006-09       Impact factor: 9.139

Review 7.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  Characterization of a murine model of Ureaplasma urealyticum pneumonia.

Authors:  Rose M Viscardi; Jennifer Kaplan; Judith C Lovchik; Ju Ren He; Lisa Hester; Srinivas Rao; Jeffrey D Hasday
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Authors:  R Doug Hardy; Jacqueline J Coalson; Jay Peters; Adriana Chaparro; Chonnamet Techasaensiri; Angelene M Cantwell; T R Kannan; Joel B Baseman; Peter H Dube
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.